{'fraction_non_alphanumeric': 0.020697167755991286, 'fraction_numerical': 0.0010893246187363835, 'mean_word_length': 5.006535947712418, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Evaluation of chemosensitivity in the 6-day subrenal capsule assay].

The antitumor activity of chemotherapeutic agents can be evaluable faster by subrenal capsule assay (SRCA), and the activity ratings between SRCA and subcutaneous transplantation assay in nude mice were correlated well. Thus, SRCA can be utilized as a disease-oriented screening in vivo instead of a human tumor-nude mice system in the future. The original SRCA method developed by A.E. Bogden is a chemosensitivity test which is carried out in easy procedure. But because of infiltration of host cells derived by a host immune reaction, the chemosensitivity results in SRCA may be modified and so further work must be attempted to get exact results of chemosensitivity and good clinical correlation. Although, SRCA has a high possibility of application on an individual basis for prediction of chemosensitivity and it was discussed in this paper.